Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with ...
The candidate uses the same basic mRNA technology implemented in Moderna’s covid-19 vaccines to accomplish this. mRNA vaccines prompt the body’s cells to produce a target protein that’s then ...
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 ... The convenience of a combination shot could draw some of the 150 million Americans who receive ...
(Reuters) -Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its ...